Immunomedics Reports Results of Lymphoma Therapy With Veltuzumab

Immunomedics, Inc., … Tuesday announced that subcutaneous injections of low doses of veltuzumab in patients with non-Hodgkin’s lymphoma (NHL) achieved sustained serum levels of pharmacologically active antibody, with objective response rates comparable to those seen with higher intravenous doses.
CNNMoney